Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Tempest Therapeutics, Inc. issued 2,344,828 shares of warrant to holder of existing warrants for cash exercise of 1,172,414 shares at $1.73 per share, aggregate gross proceeds approx $2.0 million.
- Security
- warrant
- Shares
- 2,344,828 shares
- Purchaser
- holder of existing warrants
- Consideration
- cash exercise of 1,172,414 shares at $1.73 per share, aggregate gross proceeds approx $2.0 million
Exact text from the filing
Pursuant to the Inducement Letter, the holder agreed to exercise for cash the Existing Warrants to purchase an aggregate of 1,172,414 shares of the Company’s common stock at a reduced exercise price of $1.73 per share in consideration of the Company’s agreement to issue to the holder a new unregistered common stock purchase warrant (the “ New Warrant ”) to purchase up to 2,344,828 shares of common stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Tempest Therapeutics, Inc. entered into Inducement Letter with a holder of certain existing warrants to purchase shares of the Company’s common stock valued at approximately $2.0 million (effective 2026-05-28).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- a holder of certain existing warrants to purchase shares of the Company’s common stock
- Value
- approximately $2.0 million
- Effective
- 2026-05-28
Exact text from the filing
On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock
View on SEC.gov